This multicenter, prospective, observational study aims to address two primary objectives.
The first objective is to demonstrate that hospital-acquired pneumonia (nosocomial pneumonia) following cardiac surgery can be predicted using artificial intelligence (AI), and to develop a personalized risk calculator for its development.
The second objective is to demonstrate that hospital-acquired pneumonia can serve as a risk factor for a 1-year composite cardiovascular and pulmonary outcome after cardiac surgery, and to develop a personalized risk calculator for this composite outcome.
The composite outcome will include the occurrence of any of the following events:
* Respiratory death * Hospitalization for respiratory diseases * Development of oxygen dependence * New-onset asthma, COPD, or interstitial lung disease * Initiation or intensification of bronchodilator or corticosteroid therapy * Cardiovascular death * Acute myocardial infarction * Unstable angina * Myocardial revascularization * Acute ischemic stroke * Transient ischemic attack * Acute heart failure * Hospitalization for decompensated heart failure * New-onset atrial fibrillation or ventricular tachycardia * Initiation or intensification of antiarrhythmic therapy Both objectives will be addressed using artificial intelligence technologies applied during the data analysis phase.
This is a non-interventional study. Patient evaluation and treatment are conducted in strict accordance with approved standards of medical care for the respective conditions. No experimental or unregistered (not approved for use in the Russian Federation) medical or diagnostic procedures will be performed during this study.
Age ≥ 18 years;
Cardiac and/or vascular surgical intervention during the current hospitalization;
Signed informed consent from the patient for the use of their anonymized data for scientific purposes.
Use of systemic antibacterial drugs within 30 days prior to the surgical intervention;
Prescription of systemic antibacterial drugs during the hospitalization period for any indication other than hospital-acquired pneumonia;
HIV infection.
Patients of 18 years and older after cardiac and/or vascular surgical intervention during the current hospitalization
Other
Prospective
Not applicable- observational study
Other interventionNot applicable- observational study
Hospital acquired pneumonia
Occurrence of hospital-acquired pneumonia
Composite cardiovascular and pulmonary endpoint
Occurrence of the composite cardiovascular and pulmonary endpoint
Non-pneumonia postoperative complications
Incidence of non-pneumonia postoperative complications (surgical site infections, cardiac events, etc.)
Composite Pulmonary Outcome
Incidence of the Composite Pulmonary Outcome: Respiratory death; Hospitalization due to respiratory diseases; New-onset oxygen dependence; New-onset asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease (ILD); Initiation or intensification of bronchodilator or corticosteroid therapy
Composite Cardiovascular Outcome
Incidence of the Composite Cardiovascular Outcome: Cardiovascular death; Acute myocardial infarction; Unstable angina; Myocardial revascularization; Acute ischemic stroke (acute cerebrovascular accident); Transient ischemic attack (TIA); Acute heart failure; Hospitalization for decompensated heart failure; New-onset atrial fibrillation or ventricular tachycardia; Initiation or intensification of antiarrhythmic therapy
Click on the lead sponsor to view all of their trials.
Tomsk National Research Medical Center of the Russian Academy of Sciences
Lead sponsor
National Research Tomsk State University
Collaborator
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Collaborator